Skip to content

Celcuity CELC Return on equity

Return on equity at other companies

Eli Lilly logo
Eli LillyLLY
107.6%+29.9pp
Gilead Sciences logo
Gilead SciencesGILD
43.2%+10.7pp
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-40%-4.3pp
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-85.7%+1.7pp
Tango Therapeutics logo
Tango TherapeuticsTNGX
-38.4%-10.5pp
CG Oncology logo
CG OncologyCGON
-20.8%+7.1pp

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Calculated from Celcuity’s reported figures.

Based on trailing twelve months.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's return on equity?
Celcuity (CELC) reported return on equity of -275.2% in Q1 2026.
How has Celcuity's return on equity changed year-over-year?
Celcuity's return on equity decreased by 138.5% year-over-year, from -115.4% to -275.2%.
What is the long-term trend for Celcuity's return on equity?
Over 5 years (2020 to 2025), Celcuity's return on equity has grown at a 21.8% compound annual growth rate (CAGR), from -61.1% to -163.8%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.